ChinaAMC Hang Seng Biotech ETF (03069.HK) Rises 1.07% Intraday after Akeso's HK$1.955 Billion Discounted Placement

NewTimeSpace News: As of 9:55 on October 15, the ChinaAMC Hang Seng Biotech ETF (03069.HK) rose 1.07% to a latest price of HK$15.150. The ETF has traded 3.8239 million units so far today for a turnover of HK$57.8129 million at an average price of HK$15.119, with a turnover rate of 1.62%. It is down 4.42% so far this week. Its current net asset value per unit is HK$15.0261, and its assets under management stand at HK$3.549 billion.

(Note on scope: the net asset value per unit and assets under management are as of October 14, 2026; the week-to-date change is measured against the closing price of HK$15.850 on October 9.)

On the news front, Akeso announced on October 14 that it would place 20 million new shares at HK$97.76 each, raising gross proceeds of about HK$1.955 billion and net proceeds of about HK$1.941 billion after expenses; the placement price represents a discount of about 6.9% to the closing price of HK$105.00 on October 13, and the company's shares closed down 9.62% that day. About 85% of the proceeds will be used for global and China innovation pipelines and R&D platform development, about 5% for commercialisation of approved products, and the deal is expected to complete on or before October 16.

The ChinaAMC Hang Seng Biotech ETF (03069.HK) is a passively managed exchange-traded fund under the ChinaAMC Global ETF Series, with the investment objective of closely tracking the performance of the Hang Seng Biotech Index. The index is compiled by Hang Seng Indexes Company on a net total return basis and selects the 30 largest biotech companies listed in Hong Kong that are eligible for Southbound trading, including pre-revenue companies listed under Chapter 18A of the Listing Rules; its constituents span the Hang Seng Industry Classification System sub-sectors of biotechnology, pharmaceuticals, pharmaceutical distribution, pharmaceutical and biotech contract services, and medical devices and supplies, weighted by freefloat-adjusted market capitalisation with a 10% cap on any single constituent.

Tianfeng Securities noted that, according to Pharmacube data, the total value of China's innovative drug licence-out deals reached US$99.7 billion in the first half of 2026, about twice the full-year 2024 level and 73% of the full-year 2025 level, making the out-licensing of overseas rights a key source of funding for Chinese companies; among the 38 innovative drugs approved in the same period, 11 were new-target, new-mechanism products and all were independently developed in China, as the industry moves from an investment phase into a phase of delivering results.